FDA anti-asthma drug bioequivalence guidance
Executive Summary
Outlines protocol for testing metaproterenol sulfate and albuterol metered dose inhalers in a randomized, single dose, two-way, crossover study of 60 mild-to-moderate asthmatics. Copies of the guidance are available from FDA's Division of Bioequivalence, Parklawn Building, 5600 Fishers Lane, Rockville, MD.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.